Consent in legitimacy. Integrity, legitimacy…
True.
Techniques.
Makes sense. Do you think this is something that the private sector can help?….Obviously, it won’t happen with the private sector alone. It would happen with the administration creating the infrastructure.
Poster boy.
I see.
What can we do?
Before us?
A paper stamp.
Let me tell you what sort of assets we have.
As I was saying before, we have a few medical centers using our platform, but the majority of our healthcare provider users are clinics.
Five or six.
This makes sense, because we’re not in the position of oncology, cancer, acute syndrome.
We are helping with chronic disease management. Naturally, this is business that the NHI is trying to push out, too.
Exactly. As a result, a majority of our software is deployed at the…
Right. As a result of having a workflow, patient management platform at the clinic, we’re able to integrate pathology, self-monitor data, prescription data.
We’re starting to run algorithms.
We create APIs. We do the heavy lifting with a different lapse, create APIs.
Build the pipes and then the water starts flowing.
Somebody needs to go out and do this.
I wouldn’t say de facto yet, we’re trying to be.
Right. As a business, that’s our strategy.
As the data starts coming up, we then run these algorithms and alert the doctors. Then the doctors make decisions.
Then when the patients use our app, they get education, they get support on managing diabetes. That’s what we do.
Now, before I go into the health data again, the whole idea about digital therapeutics is our number one chronic disease is chronic kidney related.
Chronic kidney.
Number one, and half of chronic kidney conditions are a result of diabetes.
Number three, spending, third, spending, diabetes. The fifth spending is hypertension, seven and eight, stroke and cardiac arrest. One, three, five, seven, eight, are all chronic disease related.
We’re trying to create a digital therapeutic that can make health care providers more efficient, save NHI money. That’s one thing.
Now, we were looking at a recent legislation in Germany, starting in April 2020, their equivalent of the FDA will basically approve apps and enable healthcare providers to prescribe the apps. This is the Digital Care Act.
That’s what we’re trying to do in Taiwan. That’s one thing. As a result of capturing more data, then comes through my story of why we’re working with Sean. As we collect more data, these pharmaceuticals or these third parties, in order to do further research, would want access to that type of data.
Then how do we give consent and even the economics as part of sharing economics back with the individual user…. That was the idea of working with Bitmark as a blockchain to capture legitimacy, integrity.
Exactly. Those are the main two things that we’re working on.
One of the things that I’m working with the National Development Council and NHI on, maybe we can get your support as well, is this helping Taiwan create a digital therapeutics industry. Again, traditional pharmaceuticals, molecules, created in Switzerland or created in New Jersey, at headquarters, sold around the world.
But because digital service is localized, is customized, that will not be the model like that of traditional molecules. There will be regional solutions, jurisdictional solutions that are created that can then be used in that region.
We think that Taiwan is a country that has an edge, because of what you mentioned 30 minutes ago, NHI, good practice, and the fact that we have data.
Those are the two things. The blockchain infrastructure on personal health data, and digital therapeutics is what we will continue to focus on. For however many years that may take us.
Last night. [laughs]
Servers.
For masks, yeah.
Very hard.
or train tickets.
Computation bragging rights.
Yeah.
Gain in return, yeah.
Simple language.
Interesting. All right. Is there anything else that you think that this country should be focused on with regards to health data?
